Laboratory News and Research

RSS

Light-activated diabetes drug: an interview with Dr David Hodson

We've known about chemicals that can be light-activated for about five to ten years now. They’ve mainly all been applied to neurons and, more specifically, the retina. Nobody has ever really looked at any tissues outside of the nervous system.

5 Nov 2014

Non-injectable vaccine may provide long-term protection against deadly Ebola virus

A potentially breathable, respiratory vaccine in development has been shown to provide long-term protection for non-human primates against the deadly Ebola virus, as reported this week in the online edition of the journal Molecular Pharmaceutics.

5 Nov 2014

New device facilitates diagnosis of prostate cancer

Distinguishing between benign and malignant prostate tissue is difficult. A new device facilitates the diagnosis for doctors: Through a visual analysis, they can reliably determine if they are dealing with carcinoma within a minute-and-a-half. Fraunhofer researchers will be presenting the prototype at the COMPAMED trade fair in Düsseldorf from November 12th to 14th.

5 Nov 2014

Research findings could pave way for new treatments against filoviruses

Filoviruses like Ebola "edit" genetic material as they invade their hosts, according to a study published this week in mBio, the online open-access journal of the American Society for Microbiology.

5 Nov 2014

Study suggests possible link between body fat and risk of immunotherapy toxicity

Immunotherapy that can be effective against tumors in young, thin mice can be lethal to obese ones, a new study by UC Davis researchers has found.

4 Nov 2014

Hemp Health launches CBD wellness supplements

Hemp Health Inc., a pioneer in hemp cannabidiol (CBD) products, today launched their line of CBD wellness supplements. Available in oil, spray and capsule form, Hemp Health's products offer a compelling alternative to medical marijuana. The CBD supplements provide consumers with the therapeutic ingredient in hemp while allowing them to avoid the negative mental and physical effects of marijuana.

4 Nov 2014

Health impacts of inhalable constituents of thirdhand smoke

Ever walked into a hotel room and smelled old cigarette smoke? While the last smoker may have left the room hours or even days ago, the lingering odors—resulting from noxious residue that clings to walls, carpets, furniture, or dust particles—are thanks to thirdhand smoke.

4 Nov 2014

Astellas, Dana-Farber to develop K-Ras inhibitors for treatment of lung, pancreatic cancers

Dana-Farber Cancer Institute (Dana-Farber) and Astellas Pharma Inc. today announced a three-year collaboration to research and develop small molecule inhibitors of oncogenic K-Ras for the treatment of cancer, including lung cancer.

4 Nov 2014

MSD announces Phase 2b results of doravirine therapy in untreated patients with HIV-1 infection

Merck Sharp & Dohme Ltd. MSD (known as Merck & Co., Inc. in the United States and Canada), today announced the presentation of results from a Phase 2b clinical trial evaluating the safety and efficacy of once daily oral doravirine, an investigational next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI), plus tenofovir/emtricitabine (TDF/FTC) compared to efavirenz plus TDF/FTC in previously untreated patients with HIV-1 infection.

4 Nov 2014

EBioMedicine: Open access journal from Elsevier

Elsevier is a world-leading provider of scientific, technical and medical information products and services. Two of its leading brands, Cell Press and The Lancet, have now joined forces to launch a new open access journal, EBioMedicine.

4 Nov 2014

CytRx provides overview of clinical development programs, reports 2014 Q3 financial results

CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today reported financial results for the three months ended September 30, 2014, and also provided an overview of recent accomplishments by and upcoming milestones for its clinical development programs.

4 Nov 2014

Innovative tool could redefine limits of synthetic biology, improve study of yeast genetics

NYU Langone yeast geneticists report they have developed a novel tool -- dubbed "the telomerator" -- that could redefine the limits of synthetic biology and advance how successfully living things can be engineered or constructed in the laboratory based on an organism's genetic, chemical base-pair structure.

4 Nov 2014

Scientists obtain first structure of the immature form of HIV

Scientists at the European Molecular Biology Laboratory in Heidelberg, Germany and collaborators from Heidelberg University, in the joint Molecular Medicine Partnership Unit, have obtained the first structure of the immature form of HIV at a high enough resolution to pinpoint exactly where each building block sits in the virus.

4 Nov 2014

UC Davis researchers link increased body fat and lethal drug reactions in mice

Immunotherapy that can be effective against tumors in young, thin mice can be lethal to obese ones, a new study by UC Davis researchers has found. The findings, published online today in The Journal of Experimental Medicine, suggest a possible link between body fat and the risk of toxicity from some types of immunotherapy.

3 Nov 2014

Findings could lead to single blood test for early detection of many types of cancer

Scientists have identified more than 800 markers in the blood of cancer patients that could help lead to a single blood test for early detection of many types of cancer in future, according to research presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool today (Sunday).

3 Nov 2014

New research sheds light on future efforts to eradicate HIV from the body in human patients

Where does HIV hide? Antiretroviral drugs can usually control the virus, but can't completely eliminate it. So any strategy to eradicate HIV from the body has to take into account not only the main group of immune cells the virus targets, called CD4 or helper T cells, but other infected cells as well.

3 Nov 2014

FDA approves Fluzone High-Dose vaccine sBLA to include efficacy data in Prescribing Information

Sanofi Pasteur, the vaccines division of Sanofi, today announced that the U.S. Food and Drug Administration has approved the supplemental biologics license application (sBLA) for Fluzone High-Dose (Influenza Vaccine) to include efficacy data in the Prescribing Information.

3 Nov 2014

Gates Foundation awards US$156 million to support PATH Malaria Vaccine Initiative

In support of a bold quest to rid the world entirely of malaria, the Bill & Melinda Gates Foundation today announced an award of US$156 million to PATH to support the PATH Malaria Vaccine Initiative (MVI) in building new vaccines that will interrupt the cycle of malaria parasite transmission and help realize the "accelerating to zero" agenda. Such vaccines would ensure that parasite reintroduction is prevented by providing what could be called an "immunological bed net."

3 Nov 2014

Eribulin drug could extend life of women with advanced triple negative breast cancer

THE cancer drug eribulin, originally developed from sea sponges, could give women with advanced triple negative breast cancer an average of five extra months of life, according to research presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool today (Monday).

3 Nov 2014

Researchers develop mouse model to improve basic research on Ebola treatments, vaccines

Researchers at the University of North Carolina at Chapel Hill and colleagues have developed the first genetic strain of mice that can be infected with Ebola and display symptoms similar to those that humans experience.

31 Oct 2014

Laboratory News and Research

Light-activated diabetes drug: an interview with Dr David Hodson

Non-injectable vaccine may provide long-term protection against deadly Ebola virus

New device facilitates diagnosis of prostate cancer

Research findings could pave way for new treatments against filoviruses

Study suggests possible link between body fat and risk of immunotherapy toxicity

Hemp Health launches CBD wellness supplements

Health impacts of inhalable constituents of thirdhand smoke

Astellas, Dana-Farber to develop K-Ras inhibitors for treatment of lung, pancreatic cancers

MSD announces Phase 2b results of doravirine therapy in untreated patients with HIV-1 infection

EBioMedicine: Open access journal from Elsevier

CytRx provides overview of clinical development programs, reports 2014 Q3 financial results

Innovative tool could redefine limits of synthetic biology, improve study of yeast genetics

Scientists obtain first structure of the immature form of HIV

UC Davis researchers link increased body fat and lethal drug reactions in mice

Findings could lead to single blood test for early detection of many types of cancer

New research sheds light on future efforts to eradicate HIV from the body in human patients

FDA approves Fluzone High-Dose vaccine sBLA to include efficacy data in Prescribing Information

Gates Foundation awards US$156 million to support PATH Malaria Vaccine Initiative

Eribulin drug could extend life of women with advanced triple negative breast cancer

Researchers develop mouse model to improve basic research on Ebola treatments, vaccines

Pittcon 2024 - Advancing Science on the West Coast eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics